ExeVir
Professor Xavier Saelens, scientific founder of Exevir is a Group Leader at the VIB-UGent Center for Medical Biotechnology at VIB and a full Professor Molecular Virology at Ghent University.
His research is primarily focused on influenza and respiratory syncytial virus. The aim of this research is to develop new vaccines and antibody-based intervention strategies to prevent and treat disease caused by these and other important human respiratory viruses. A second line of research in the Saelens group aims to increase knowledge on the molecular interactions between influenza and respiratory syncytial virus and their human host.
This person is not in any offices
ExeVir
Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.